FIG. 1.

Survival analysis of sporadic lesions and radiation-associated undifferentiated pleomorphic sarcoma (RA-UPS)/malignant fibrous histiocytoma (MFH). a Overall survival (OS) of 1069 patients with UPS. The 1-, 3-, and 5-year OS rates were respectively 90.1, 70.2 and 60.5 % for sporadic lesions versus 83.5, 55.4, and 47.0 % for RA-UPS. b Disease-specific survival (DSS) was similarly worse for the RA-UPS patients. The 1-, 3-, and 5-year DSS rates were respectively 94.1, 82.7 and 76.4 % for sporadic lesions versus 86.9, 59.2, and 52.2 % for RA-UPS. c In this study, 98 sporadic patients were matched with 55 RA-UPS patients based on tumor size, age, and anatomic distribution. The OS was worse in the sporadic group (median survival, 11.8 years for sporadic lesions vs 3.6 years for RA-UPS). d The DSS also was worse for the RA-UPS group (median DSS, 22 years vs 5.2 years in the RA-UPS group). e The 1-, 3-, and 5-year local recurrence-free survival rates were respectively 94.7, 80.9, and 74.5 % for sporadic lesions versus 76.7, 45.1, and 42.4 % for RA-UPS. f The 1-, 3-, and 5-year distant recurrence-free survival rates were respectively 84.8, 67.6, and 62.6 % for sporadic lesions versus 92.3, 74.1, and 71.1 % for RA-UPS (statistically nonsignificant difference)